Vaccine-associated paralytic poliomyelitis: a case report of domiciliary transmission

Paz, José A; Vallada, Marcelo G; Marques, Silvia N. C. H; Casella, Erasmo B; Marques, Heloisa H. S; Marques-Dias, Maria J.
Rev. Hosp. Clin. Fac. Med. Univ. Säo Paulo ; 55(3): 101-4, May-June 2000. tab
Artigo em Inglês | LILACS | ID: lil-273571

Documentos relacionados

  1. Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3.
  2. The Evolutionary Pathway to Virulence of an RNA Virus.
  3. Coordinated Response to Imported Vaccine-Derived Poliovirus Infection, Barcelona, Spain, 2019-2020.
  4. Experimental Evolution to Study Virus Emergence.
  5. Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.
  6. Observational analysis of the immunogenicity and safety of various types of spinal muscular atrophy vaccines.
  7. Considerations for the Full Global Withdrawal of Oral Polio Vaccine After Eradication of Polio.
  8. Polio eradication: Addressing the hurdles on the last mile.
  9. Antivenoms, hepatitis B vaccine and oral polio vaccine can be considered for storage and handling outside the cold chain following the innovative 'controlled temperature chain' approach.
  10. Polio endgame finish is in sight.